Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Brahmer, Julie R.
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph Matthias
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Bristol Myers Squibb Co, Princeton, NJ USA
[8] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8030
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ASSOCIATION OF TUMOR PD-L1 EXPRESSION AND IMMUNE BIOMARKERS WITH CLINICAL ACTIVITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538)
    Antonia, Scott J.
    Grosso, Joseph F.
    Horak, Christine E.
    Harbison, Christopher T.
    Kurland, John F.
    Inzunza, H. David
    Gupta, Ashok
    Sankar, Vindira
    Park, Jong-Soon
    Jure-Kunkel, Maria
    Novotny, James
    Cogswell, John
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Simon, Jason
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S907 - S908
  • [22] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Brahmer, J. R.
    Gettinger, S.
    Chow, L. Q.
    Juergens, R.
    Shepherd, F. A.
    Laurie, S. A.
    Gerber, D. E.
    Goldman, J.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Borghaei, H.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2
  • [23] LONG-TERM SURVIVAL OF IPILIMUMAB-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PROGRAMMED DEATH-1; ANTI-PD-1; BMS-936558; ONO-4538) IN A PHASE I TRIAL
    Hodi, Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne L.
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William H.
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert A.
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok
    Sosman, Jeffrey A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 177 - 177
  • [24] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Gerber, David E.
    Goldman, Jonathan Wade
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Borghaei, Hossein
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)
    Gettinger, S.
    Chow, L. Q.
    Borghaei, H.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S34 - S35
  • [26] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie R.
    Juergens, Rosalyn
    Shepherd, Frances A.
    Laurie, Scott A.
    Gerber, David E.
    Goldman, Jonathan
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Gettinger, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S153 - S153
  • [27] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [30] Safety, durable clinical benefit, and remission resulting from nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC); long-term patient follow-up
    Drake, C. G.
    Mcdermott, D. F.
    Sznol, M.
    Choueiri, T. K.
    Kluger, H. M.
    Powderly, J. D.
    Smith, D. C.
    Sankar, V.
    Gutierrez, A. A.
    Wigginton, J. M.
    Gupta, A.
    Atkins, M. B.
    BJU INTERNATIONAL, 2013, 112 : 9 - 10
12345